What is the share price of Lupin Limited (LUPIN) today?
The share price of LUPIN as on 13th November 2026 is ₹1980.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Lupin Limited (LUPIN) share?
The past returns of Lupin Limited (LUPIN) share are- Past 1 week: -0.26%
- Past 1 month: 2.34%
- Past 3 months: -12.00%
- Past 6 months: -10.62%
- Past 1 year: -3.54%
- Past 3 years: 68.79%
- Past 5 years: 109.61%
What are the peers or stocks similar to Lupin Limited (LUPIN)?
The peers or stocks similar to Lupin Limited (LUPIN) include:What is the dividend yield % of Lupin Limited (LUPIN) share?
The current dividend yield of Lupin Limited (LUPIN) is 0.91.What is the market cap of Lupin Limited (LUPIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Limited (LUPIN) is ₹90557.73 Cr as of 13th November 2026.What is the 52 week high and low of Lupin Limited (LUPIN) share?
The 52-week high of Lupin Limited (LUPIN) is ₹2529.50 and the 52-week low is ₹1892.90.What is the PE and PB ratio of Lupin Limited (LUPIN) stock?
The P/E (price-to-earnings) ratio of Lupin Limited (LUPIN) is 15.70. The P/B (price-to-book) ratio is 4.02.Which sector does Lupin Limited (LUPIN) belong to?
Lupin Limited (LUPIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Lupin Limited (LUPIN) shares?
You can directly buy Lupin Limited (LUPIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Lupin Limited
LUPIN Share Price
NSELUPIN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LUPIN Performance & Key Metrics
LUPIN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.39 | 4.02 | 0.91% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.36 | 6.07 | 0.47% |
from 33 analysts
Price Upside
Earnings Growth
Rev. Growth
LUPIN Company Profile
Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
LUPIN Sentiment Analysis
LUPIN Sentiment Analysis
LUPIN Stock Summary · August 2026
Management delivered a strong quarter overall, highlighting record revenue and continued margin expansion even as it flagged near-term pressure in the U.S. Revenue from operations rose 32% year over year to INR 8,277 crores, while EBITDA excluding forex and other income increased 50% to INR 2,464 crores and EBITDA margin improved to 30%. Management stressed that growth was broad-based and marked the 16th consecutive quarter of year-on-year expansion, with India formulations rising 13.9% and India diabetes up 31.8%, helped by semaglutide and leadership in Huminsulin. Emerging markets also grew sharply, with Brazil, South Africa and the Philippines driving 52% growth. At the same time, the U.S. business faced intensified competition in Mirabegron and growing pressure in Tolvaptan, and management said revenue could soften over the next couple of quarters. They kept their full-year U.S. revenue guidance at USD 1.1 billion to USD 1.2 billion, while pointing to more than 50 planned U.S. launches over three years, including biosimilars, respiratory products and Apixaban, as the path to restoring U.S. growth from FY28 onward.
LUPIN Stock Growth Drivers
LUPIN Stock Growth Drivers
13Record Quarterly Financial and Operating Momentum
Lupin delivered a standout quarter with total revenue from operations above INR 8,000 crores and
Broad-Based Geographic Growth and India Outperformance
The company’s growth was supported by broad geographic momentum, with ex-U.S. organic revenue rising more
LUPIN Stock Challenges
LUPIN Stock Challenges
6U.S. revenue and margin pressure from rising competition
The company’s near-term U.S. performance is expected to weaken after a strong first quarter as
Earnings drag from rising costs and weaker non-operating income
Profitability is being pressured by a combination of higher operating expenses, lower other income, and
LUPIN Forecast
LUPIN Forecasts
Price
Revenue
Earnings
LUPIN Share Price Forecast
LUPIN Share Price Forecast
All values in ₹
All values in ₹
LUPIN Company Revenue Forecast
LUPIN Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
LUPIN Stock EPS (Earnings Per Share) Forecast
LUPIN Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
LUPIN
LUPIN
Income
Balance Sheet
Cash Flow
LUPIN Income Statement
LUPIN Income Statement
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | sep 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,668.11 | 5,715.02 | 5,821.42 | 5,724.08 | 6,347.38 | 7,137.51 | 7,282.22 | 7,615.37 | 8,407.21 | 7,954.06 | ||||||||||
| Operating & Other expenses | 4,359.36 | 4,332.37 | 4,411.81 | 4,345.96 | 4,541.10 | 4,706.18 | 5,332.24 | 5,120.42 | 5,827.36 | 5,782.85 | ||||||||||
| EBITDA | 1,308.75 | 1,382.65 | 1,409.61 | 1,378.12 | 1,806.28 | 2,431.33 | 1,949.98 | 2,494.95 | 2,579.85 | 2,171.21 | ||||||||||
| Depreciation/Amortization | 247.71 | 256.92 | 271.45 | 393.18 | 298.98 | 316.77 | 312.96 | 446.79 | 452.85 | 485.90 | ||||||||||
| PBIT | 1,061.04 | 1,125.73 | 1,138.16 | 984.94 | 1,507.30 | 2,114.56 | 1,637.02 | 2,048.16 | 2,127.00 | 1,685.31 | ||||||||||
| Interest & Other Items | 68.01 | 70.87 | 66.89 | 89.10 | 91.76 | 107.59 | 114.98 | 120.16 | 109.64 | 105.71 | ||||||||||
| PBT | 993.03 | 1,054.86 | 1,071.27 | 895.84 | 1,415.54 | 2,006.97 | 1,522.04 | 1,928.00 | 2,017.36 | 1,579.60 | ||||||||||
| Taxes & Other Items | 191.72 | 202.23 | 216.11 | 123.32 | 196.51 | 529.05 | 346.49 | 467.66 | 602.36 | 424.34 | ||||||||||
| Net Income | 801.31 | 852.63 | 855.16 | 772.52 | 1,219.03 | 1,477.92 | 1,175.55 | 1,460.34 | 1,415.00 | 1,155.26 | ||||||||||
| EPS | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 | 32.36 | 25.74 | 34.83 | 30.95 | 25.27 |
LUPIN Company Updates
Investor Presentation
LUPIN Stock Peers
LUPIN Past Performance & Peer Comparison
LUPIN Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lupin Limited | 15.70 | 4.02 | 0.91% |
| Sun Pharmaceutical Industries Limited | 36.15 | 5.38 | 0.85% |
| Torrent Pharmaceuticals Ltd | 80.71 | 10.10 | 0.72% |
| Laurus Labs Ltd | 147.36 | 24.11 | 0.08% |
LUPIN Stock Price Comparison
Compare LUPIN with any stock or ETFLUPIN Holdings
LUPIN Shareholdings
LUPIN Promoter Holdings Trend
LUPIN Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
LUPIN Institutional Holdings Trend
LUPIN Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
LUPIN Shareholding Pattern
LUPIN Shareholding Pattern
LUPIN Shareholding History
LUPIN Shareholding History
Mutual Funds Invested in LUPIN
Mutual Funds Invested in LUPIN
No mutual funds holding trends are available
Top 5 Mutual Funds holding Lupin Limited
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2545% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months -0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/346 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0670% | Percentage of the fund’s portfolio invested in the stock 0.89% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/94 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0028% | Percentage of the fund’s portfolio invested in the stock 2.48% | Change in the portfolio weight of the stock over the last 3 months -0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/51 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing LUPIN stock
smallcases containing LUPIN stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Lupin Limited
LUPIN Events
LUPIN Events
LUPIN Dividend Trend
LUPIN has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.89%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.89 every year
Dividends
Corp. Actions
Announcements
Legal Orders
LUPIN Dividend Trend
LUPIN has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.89%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.89 every year
LUPIN Upcoming Dividends
LUPIN Upcoming Dividends
No upcoming dividends are available
LUPIN Past Dividends
LUPIN Past Dividends
Cash Dividend
Ex DateEx DateJul 17, 2026
Dividend/Share
₹18.00
Ex DateEx Date
Jul 17, 2026
Cash Dividend
Ex DateEx DateJul 25, 2025
Dividend/Share
₹12.00
Ex DateEx Date
Jul 25, 2025
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹8.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2022
LUPIN Stock News & Opinions
LUPIN Stock News & Opinions
Lupin Ltd share price gained 0.15% to Rs 2015.0. The Company's net profit dropped 18.47% to Rs 1155.3 crore, while revenue from operations eased by 5.25% to Rs 7785.52 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.14%. It has improved by 2.03% over last one week and crept higher by 1.77% in last one month while the market capitalization of Lupin Ltd has inched up 0.85% and 14.61% in the same period respectively. Profit before tax (PBT) of Lupin Ltd stood at Rs 1579.6 crore in Q3 FY26, tumbling by 21.29% year-on-year, and nosediving by 21.70% quarter-on-quarter. EBITDA came in at Rs 1918 crore, dropping 14.82% YoY and plunging by 17.32% sequentially. Total expenses slightly declined by 0.18% to Rs 6268.75 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1310.74 crore, slightly declining by 0.07% YoY, while employee benefits expense was at Rs 1423.58 crore, inching up 2.93% YoY. For the TTM ended FY26, revenue from operations jumped by 23.86% to Rs 27487.54 crore, while net profit soared by 61.98% to Rs 5355.47 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 529273% to Rs 8391.55 crore, and PBT witnessed a strong rise of 71.17% to Rs 6872.55 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7334.5 crore in FY26, as against Rs 2999.94 crore in FY25. Lupin Ltd ticked higher by 0.84% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 7.38% during the same period.
Lupin Ltd share price ticked higher by 0.77% to Rs 2012.0. The Company's net profit contracted by 18.47% to Rs 1155.3 crore, while revenue from operations softened by 5.25% to Rs 7785.52 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 4.36%. It has improved by 1.84% over last one week and moved up slightly by 1.37% in last one month while the market capitalization of Lupin Ltd has marginally improved by 2.08% and 15.86% in the same period respectively. Profit before tax (PBT) of Lupin Ltd stood at Rs 1579.6 crore in Q3 FY26, plunging by 21.29% year-on-year, and tumbling by 21.70% quarter-on-quarter. EBITDA came in at Rs 1918 crore, dropping 14.82% YoY and nosediving by 17.32% sequentially. Total expenses marginally dropped 0.18% to Rs 6268.75 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1310.74 crore, slightly declining by 0.07% YoY, while employee benefits expense was at Rs 1423.58 crore, ticking higher by 2.93% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 23.86% to Rs 27487.54 crore, while net profit jumped 61.98% to Rs 5355.47 crore, compared to previous TTM. EBITDA jumped by 529273% to Rs 8391.55 crore, and PBT soared 71.17% to Rs 6872.55 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7334.5 crore in FY26, as against Rs 2999.94 crore in FY25. Lupin Ltd inched up 1.32% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.
Lupin Limited announced the appointment of Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 3, 2026, and as an Independent Director for a term of five consecutive years with effect from November 3, 2026, to November 2, 2031, subject to member approval. Gupta, a Chartered Accountant with extensive experience including a previous role as Vice Chairman of Bharti Enterprises Limited, currently serves as Chairman of 360 ONE WAM Limited, Coforge Limited, and Valuedrive Technologies Limited, among other positions.
Lupin Ltd is up for a third straight session today. The stock is quoting at Rs 2012.2, up 1.12% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.7% on the day, quoting at 23097.15. The Sensex is at 74708.52, up 0.75%. Lupin Ltd has slipped around 0.94% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 3.45% in last one month and is currently quoting at 26710.8, up 1.9% on the day. The volume in the stock stood at 3.26 lakh shares today, compared to the daily average of 6.58 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2016.8, up 1.1% on the day. Lupin Ltd is up 2.48% in last one year as compared to a 10.21% slide in NIFTY and a 22.74% slide in the Nifty Pharma index.The PE of the stock is 13.8 based on TTM earnings ending June 26.
Lupin Limited announced that its Nomination and Remuneration Committee has granted 40,157 stock options to employees of the company and its subsidiaries under the Lupin Employees Stock Option Scheme 2025, with an exercise price of Rs 2.00 per option, vesting over a three-year period beginning one year from October 19, 2026.
Lupin Limited will hold a board meeting on Tuesday, November 03, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for company insiders will be closed from Thursday, October 01, 2026, and will reopen on Friday, November 06, 2026.
Lupin Limited, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, has forwarded a certificate received from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, the company’s Registrar and Share Transfer Agent, for the quarter ended September 30, 2026.
Lupin Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Lupin Limited announced that its Operations and Finance Committee has allotted 24111 fully paid-up equity shares of Rs 2/- each, following the exercise of vested options granted to employees of the company and its subsidiaries under its stock option plans, increasing the issued and paid-up share capital to Rs 91,45,79,944 consisting of 45,72,89,972 equity shares of Rs 2/- each.
Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2104.3, down 0.02% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75160.39, down 0.55%.Lupin Ltd has lost around 8.51% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 3.18 lakh shares today, compared to the daily average of 9.12 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2110.4, up 0.24% on the day. Lupin Ltd jumped 6.29% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.The PE of the stock is 14.58 based on TTM earnings ending June 26.

Over the last 5 years, revenue has grown at a yearly rate of 13.67%, vs industry avg of 10.75%
Over the last 5 years, market share increased from 5.03% to 5.66%
Over the last 5 years, net income has grown at a yearly rate of 34.39%, vs industry avg of 10.44%